Holen Sie sich die Stockscreener-App
136.01
1.21%
1.63
Vorhandelsmarkt:
136.19
0.18
+0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$134.38
Offen:
$134
24-Stunden-Volumen:
5.75M
Relative Volume:
0.88
Marktkapitalisierung:
$233.36B
Einnahmen:
$42.34B
Nettoeinkommen (Verlust:
$13.50B
KGV:
17.64
EPS:
7.71
Netto-Cashflow:
$6.66B
1W Leistung:
+2.06%
1M Leistung:
+1.82%
6M Leistung:
+20.25%
1J Leistung:
+30.89%
1-Tages-Spanne:
$134.00
$136.26
1-Wochen-Bereich:
$132.38
$139.06
52-Wochen-Spanne:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
136.01 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
107.41 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.63 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.21 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
India Medical Nutrition Market Future Trends and Scope Analysis - openPR.com
Abbott, MSD Forge Diabetes‑Drug Pact For Wider Indian Reach - BW Healthcare World
Abbott Labs stock price target maintained at $140 by Oppenheimer - Investing.com India
Leerink Partners Begins Coverage on ABT - Insider Monkey
10 Best Dividend Stocks to Buy for Dependable Dividend Growth - Insider Monkey
Who Rules Homecare Clinical Nutrition Market? Abbott, Danone, - openPR.com
Health Canada approves Abbott’s i-STAT TBI test for suspected concussions - Medical Device Network
Abbott, Tandem Diabetes Care Partner For Glucose-Ketone Sensor for Diabetes Management - Insider Monkey
Abbott Laboratories (ABT): Buy, Sell, or Hold Post Q1 Earnings? - FinancialContent
Abbott (ABT) Stock Dips While Market Gains: Key Facts - Nasdaq
Eaton makes a move outside of the data center — plus, what's new with Abbott Labs - CNBC
Abbott Wins Dismissal of Whistleblower’s Medicare Fraud Suit - Bloomberg Law News
Abbott Declares 406th Consecutive Quarterly Dividend - marketscreener.com
Abbott Laboratories' Whole Blood Concussion Test Approved by Health Canada - marketscreener.com
Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions - Barchart.com
Blood Screening Market Outlook | Key Players: Abbott Laboratories, Roche, Grifols, BioMérieux - openPR.com
Deep Venous Disease Treatment Market Key Players Analysis - openPR.com
1 Unpopular Stock that Should Get More Attention and 2 to Avoid - FinancialContent
Jim Cramer Calls Abbott “Really Excellent” - Insider Monkey
Electrophysiology Devices Market Share Leaders: Abbott, Acutus Medical, and Biosense Webster - openPR.com
Abbott Laboratories (ABT) Maintains Quarterly Dividend of $0.59 - GuruFocus
Abbott Declares 406Th Consecutive Quarterly Dividend, Payable on August 15, 2025 - marketscreener.com
Piper Sandler names Abbott, Edwards, Glaukos as top medtech catalyst picks - Investing.com Nigeria
Abbott Laboratories Keeps Quarterly Dividend at $0.59 per Share, Payable August 15 to Shareholders as of July 15 - marketscreener.com
Clinical Immunochemistry Analyzers Market projected reach USD 6.9 billion by 2034, growing at a CAGR of 4.4% | Exactitude Consultancy - GlobeNewswire Inc.
Abbott Laboratories Stock Sees RS Rating Rise To 82 - Investor's Business Daily
Stocks To Watch: Abbott Laboratories Sees RS Rating Rise To 82 - MSN
Abbott and Medtronic best positioned manufacturers in US neurology market - PharmaLive
Abbott Laboratories (NYSE:ABT) Partners With Tandem To Develop Dual Sensor Diabetes Solutions - simplywall.st
Tandem, Abbott team on insulin delivery with glucose-ketone sensor - MedTech Dive
Tandem Diabetes (TNDM) Partners with Abbott for Innovative Diabe - GuruFocus
Tandem, Abbott in deal to combine insulin delivery with glucose-ketone sensor - Seeking Alpha
Abbott (ABT) Partners with Tandem Diabetes for Advanced Diabetes Management Solutions | ABT Stock News - GuruFocus
3 Low-Volatility Stocks in Hot Water - FinancialContent
Abbott Laboratories Stock: Is ABT Outperforming the Health Care Sector? - MSN
Abbott Laboratories (ABT) Stock Dips Slightly on NYSE, Long-Term Gains Remain Solid - Daily Chhattisgarh News
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Thousands of lawsuits over baby formula should stay where filed, court says - Reuters
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Test Strip Market Is Booming So Rapidly 2025-2032 -Abbott - openPR.com
Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System - insights.citeline.com
Abbott Laboratories Stock: Is ABT Outperforming The Health Care Sector? - Barchart.com
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $153 From $147, Maintains Buy Rating - marketscreener.com
There's Been No Shortage Of Growth Recently For Abbott Laboratories' (NYSE:ABT) Returns On Capital - Yahoo Finance
Abbott Tendyne TMVR secures FDA clearance - BioWorld MedTech
Cardiac Marker Analyzer Market Is Booming WorldwideAbbott, Roche Diagnostics - openPR.com
Abbott Labs (ABT) Stock Ticks Lower: Gauging the Pulse and Future Price Points - Daily Chhattisgarh News
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):